DIAGNOSTICS AND THERAPEUTICS FOR HIV: GLOBAL MARKETS
|
|
- Zoe Patrick
- 5 years ago
- Views:
Transcription
1 DIAGNOSTICS AND THERAPEUTICS FOR HIV: GLOBAL MARKETS PHM058B April 2014 Kritika Chaudhari Project Analyst ISBN: X BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 3 STUDY GOALS AND OBJECTIVES 3 REASONS FOR DOING THE STUDY 3 INTENDED AUDIENCE 3 SCOPE AND FORMAT 3 METHODOLOGY 4 ANALYST'S CREDENTIALS 4 INFORMATION SOURCES 4 MARKET ANALYSES AND FORECASTS 4 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH ONLINE SERVICES 5 DISCLAIMER 5 CHAPTER 2 SUMMARY 7 THE SKEWED MARKET 7 HIV THERAPEUTICS MARKET WILL BE WORTH $19.6 BILLION IN FIXED-DOSE COMBINATION DRUGS AND INTEGRASE INHIBITOR DRUGS WILL DRIVE THE MARKET 2013 WHO GUIDELINES WILL EXPAND THE GLOBAL HIV MARKET 8 STRICT ADHERENCE TO ARV TREATMENT REMAINS A CHALLENGE 8 DEMAND FOR ACCESS TO AFFORDABLE MEDICINE 8 SEVEN OF THE EIGHT LEADING ARV DRUGS ARE ON PATENT CLIFF 9 GILEAD SCIENCES WILL CONTINUE TO DOMINATE THE HIV THERAPEUTICS MARKET POC DEVICES FOR CD4 AND VIRAL LOAD TESTING WILL DRIVE THE HIV DIAGNOSTICS MARKET THE U.S. WILL REMAIN THE LEADING NATIONAL MARKET FOR HIV 10 EARLY PROPHYLAXIS IS THE KEY TO HIV MANAGEMENT 10 HIV VACCINES-A LONG ROAD AHEAD 11 TOWARDS AN AIDS-FREE GENERATION 11 SUMMARY TABLE GLOBAL HIV MARKET, THROUGH 2018 ($ 12 SUMMARY FIGURE GLOBAL HIV MARKET, ($ CHAPTER 3 OVERVIEW 14 GLOBAL BURDEN OF HIV 14 TABLE 1 TOP 10 LEADING CAUSES OF DEATHS IN THE WORLD, 2011 (MILLIONS) 14 TABLE 2 BURDEN OF HIV BY GEOGRAPHICAL REGIONS 15 GLOBAL RESPONSE TO HIV EPIDEMIC 16 MILESTONES IN HIV RESEARCH 16 TABLE 3 MILESTONES IN THE HISTORY OF HIV 16 TARGETING HIV LIFECYCLE 17 TABLE 4 LIFE CYCLE OF HIV-THERAPEUTICS TARGET POINTS 18 DIAGNOSTIC TOOLS FOR DETECTING HIV INFECTION 19 EFFORTS FOR HIV PROPHYLAXIS 19 FUTURE OF GLOBAL HIV MARKET 20 CONCLUSION 21
3 CHAPTER 4 GLOBAL MARKET 23 GLOBAL HIV MARKET GLOBAL HIV MARKET FORECAST TO TABLE 5 FORECASTED NUMBER OF PEOPLE RECEIVING ARV THERAPY, (MILLIONS) HIV MARKET BY GEOGRAPHICAL REGIONS 24 TABLE 6 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, THROUGH 2018 ($ TABLE 7 ARV DRUGS MARKET SHARE BY GEOGRAPHIC REGIONS, (%) 24 FIGURE 1 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, ($ NORTH AMERICAN HIV MARKET 25 REGULATIONS IMPACTING THE GROWTH OF NORTH AMERICAN HIV MARKET MARKET FORECAST 26 EUROPEAN HIV MARKET 26 TABLE 8 EUROPEAN COUNTRIES BY RATES OF HIV DIAGNOSIS (%) 27 TABLE 9 PATTERN OF HIV INFECTION BY EUROPEAN REGIONS, TRENDS IN EUROPEAN HIV MARKET 27 TABLE 10 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES, THROUGH 2018 ($ TABLE 11 HIV THERAPEUTICS MARKET SHARE BY EU5 COUNTRIES, (%) 28 FIGURE 2 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES ($ 28 TABLE 12 HIV PREVALENCE IN EU5 COUNTRIES, TABLE 13 RATE OF LATE DIAGNOSIS BY REGIONS OF THE U.K. (%) 30 MARKET FORECAST 30 THE ASIAN HIV MARKET 31 TABLE 14 HIV PREVALENCE AND INCIDENCE OF NEW INFECTIONS IN ASIAN COUNTRIES, 2012 TABLE 15 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, THROUGH 2018 ($ TABLE 16 HIV MARKET SHARE BY LEADING ASIAN COUNTRIES, (%) 31 FIGURE 3 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, ($ TRENDS IN THE ASIAN HIV MARKET 32 MARKET FORECAST 33 HIV MARKET IN ROW 33 HIV MARKET TRENDS IN THE ROW 33 MARKET FORECAST 33 GLOBAL INVESTMENT IN HIV RESEARCH 34 TABLE 17 FORECAST GLOBAL ANNUAL INVESTMENT IN HIV RESEARCH, THROUGH 2018 ($ TABLE 18 GLOBAL INVESTMENT SHARE BY AREA OF RESEARCH, (%) 34 TABLE 19 INVESTMENT BY DONOR TYPE (%) 35 INVESTMENT IN HIV THERAPEUTICS 35 TABLE 20 INVESTMENT IN HIV THERAPEUTICS BY DRUG SUBCATEGORIES IN 2012 (%) INVESTMENT IN HIV VACCINES
4 INVESTMENT IN HIV PROPHYLAXIS 36 TABLE 21 INVESTMENT BY MODE OF HIV PROPHYLAXIS (%) 37 INVESTMENT IN HIV DIAGNOSTICS 37 INVESTMENT FOR OTHER RESEARCH ASSOCIATED WITH HIV 37 GENERIC HIV DRUGS MARKET 37 FIGURE 4 GENERIC VS. BRANDED ARV DRUGS GLOBAL SALES REVENUE, ($ FIGURE 5 GENERIC ARV DRUGS GLOBAL SALES REVENUE GROWTH ($ MILLIONS/%) 38 DRIVERS FOR THE GROWTH OF GENERIC HIV DRUGS MARKET 39 TABLE 22 LEADING ARV DRUGS ON PATENT CLIFF 39 RESTRAINTS TO THE GROWTH OF GENERIC HIV DRUGS MARKET 40 TABLE 23 DRIVERS AND RESTRAINTS OF GENERIC HIV MARKET 40 CHAPTER SUMMARY 41 TABLE 24 DRIVERS AND RESTRAINTS OF GLOBAL HIV MARKET CHAPTER 5 HIV THERAPEUTICS MARKET: LEADING ARV DRUG CATEGORIES 43 THERAPY BY LINE-TREATMENT 43 TABLE 25 RECOMMENDED ARV TREATMENT BY THE WHO 44 FIRST-LINE TREATMENT REGIMEN 44 SECOND-LINE TREATMENT REGIMEN 44 THIRD-LINE/SALVAGE TREATMENT REGIMEN 45 ARV MARKET BY DRUG CATEGORIES 45 TABLE 26 HIV THERAPEUTICS MARKET BY DRUG CATEGORY, THROUGH 2018 ($ TABLE 27 HIV THERAPEUTICS MARKET SHARE BY DRUG CATEGORY, (%) 46 FIGURE 6 HIV THERAPEUTICS MARKET BY DRUG CATEGORY (%) 46 NRTIS 47 TABLE 28 LIST OF APPROVED NRTIS (AND TABLE UNITS) 47 Mechanism of Action: 48 Resistance to NRTIs 48 Market Status 48 Market Forecast 49 NNRTIS 49 TABLE 29 LIST OF APPROVED NNRTIS 49 Mechanism of Action 50 Drug Resistance and Adverse Effects 50 Market Status 50 Market Forecast 50 PROTEASE INHIBITORS 51 TABLE 30 LIST OF APPROVED PROTEASE INHIBITORS 51 Pharmacokinetic Boosters 52 Market Forecast 52 INTEGRASE STRAND TRANSFER INHIBITORS 52 TABLE 31 LIST OF APPROVED INTEGRASE INHIBITOR DRUGS 52 Market Forecast 53 ENTRY INHIBITORS 53 TABLE 32 LIST OF APPROVED ENTRY INHIBITORS 53 Mechanism of Action 54 46
5 Market Forecast 54 SINGLE TABLET REGIMEN (STR) FIXED-DOSE COMBINATION (FDC) DRUGS 54 TABLE 33 LIST OF APPROVED STR FDC DRUGS 55 Market Forecast 55 CHAPTER SUMMARY 55 TABLE 34 MARKET DRIVERS AND RESTRAINTS OF ARV DRUGS, BY CLASS 57 CHAPTER 6 HIV THERAPEUTICS MARKET: LEADING DRUGS 59 LEADING EIGHT HIV DRUGS CLAIMED OVER 80% OF THE MARKET SHARE 59 TABLE 35 SALES REVENUE FORECAST OF LEADING HIV DRUGS, THROUGH 2018 ($ TABLE 36 HIV MARKET SHARE BY LEADING DRUGS (%) 60 FIGURE 7 HIV MARKET SHARE BY LEADING DRUGS (%) 60 ATRIPLA 61 Generic Atripla for PEPFAR Countries 61 Competitors 61 Market Forecast 61 TRUVADA 62 Truvada as a Prophylactic Drug 62 Market Forecast 62 EPZICOM 62 HLA-B*5701 Testing 63 Clinical Trials 63 Patents and Competition 63 Market Forecast 63 VIREAD 64 Viread Prodrug 64 Market Forecast 64 PREZISTA 64 Clinical Trials 64 Patents 65 Competitors 65 Market Forecast 65 REYATAZ 65 Competitors 65 Market Forecast 66 KALETRA 66 Competitors 66 Market Forecast 66 ISENTRESS 67 Clinical Trials 67 Competitors 67 Market Forecast 68 PROMISING EMERGING THERAPIES 68 STRIBILD 68 Clinical Trials 68 Competitors 69 Market Forecast 69 59
6 TIVICAY 69 Clinical Trials 70 Competitors 70 Market Forecast 70 COMPLERA 70 Clinical Trials 71 Patent 71 Market Forecast 71 INTELENCE 71 Market Forecast 72 OTHER DRUGS 72 COMBIVIR 72 Competition 72 SUSTIVA 72 NORVIR 73 SELZENTRY 73 Clinical Trials 73 Market Forecast 73 OTHER ARV DRUGS IN THE MARKET 73 CHAPTER SUMMARY 74 FIGURE 8 RANKING (BY MARKET SHARE) OF LEADING ARV DRUGS, TABLE 37 MARKET DRIVERS AND RESTRAINTS OF THE LEADING ARV DRUGS 75 CHAPTER 7 ARV DRUGS PIPELINE ANALYSIS 77 FIGURE 9 NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE 77 NRTI DRUGS IN DEVELOPMENT 78 TENOFOVIR ALAFENAMIDE (TAF) 78 Clinical Trials 78 Market Potential 78 NNRTIS IN DEVELOPMENT 79 TABLE 38 ONGOING CLINICAL TRIALS OF NNRTI DRUGS IN DEVELOPMENT 79 MK Clinical Trials 79 Market Potential 80 RILPIVIRINE (LA) 80 Clinical Trials 80 Market Potential 80 INTEGRASE INHIBITORS IN DEVELOPMENT 80 S/GSK Clinical Trials 81 Market Potential 82 ENTRY INHIBITORS IN DEVELOPMENT 82 CENICRIVIROC 82 Clinical Trials 82 Market Potential 83 ALBUVIRTIDE 83 Clinical Trials 83
7 Market Potential 83 BMS COMBINATION THERAPIES 83 TABLE 39 ONGOING CLINICAL TRIALS OF STR FDC DRUGS TRII 84 Clinical Trials 85 Market Potential 85 OTHER STR FDC DRUGS IN DEVELOPMENT 85 PHARMACOKINETIC BOOSTERS IN DEVELOPMENT 85 EMERGING THERAPIES 86 TABLE 40 ONGOING CLINICAL TRIALS OF EMERGING THERAPIES 86 SB-728-T 86 Clinical Trials 87 Market Potential 87 KP Clinical Trials 87 LEXGENLEUCEL-T (VRX-496) 88 Clinical Trials 88 Market Potential 88 SL9-TCR GENE THERAPY 88 Clinical Trials 89 IMMUNOMODULATORS 89 MONOCLONAL ANTIBODIES AGAINST HIV 89 CHAPTER SUMMARY 90 TABLE 41 OVERVIEW OF ARV DRUGS IN DEVELOPMENT 90 CHAPTER 8 HIV TESTING AND DIAGNOSTICS 93 EARLY DETECTION 93 PATIENT STAGING 93 TREATMENT SWITCHING 93 HIV SCREENING TESTS 94 HIV CONFIRMATORY TESTS 94 HIV MONITORING TESTS 94 TYPES OF HIV TESTS 94 ANTIGEN- AND ANTIBODY-BASED TESTS FOR HIV 94 TABLE 42 HIV RAPID TESTS ADVANTAGES AND DISADVANTAGES BY CLIA* COMPLEXITY AND GENERATION TABLE 43 FDA APPROVED ANTIBODY HIV TESTS 96 TABLE 44 FDA APPROVED ANTIGEN-ANTIBODY COMBO TESTS 97 CD4 TESTING 97 TABLE 45 CD4 TESTS IN THE MARKET 98 VIRAL LOAD TESTING 98 TABLE 46 LIST OF MARKETED VIRAL LOAD TESTS 99 SELECTED RAPID HIV TESTS 99 ALERE DETERMINE HIV-1/2 AG/AB COMBO TEST 99 CHEMBIO'S DPP(R) HIV 1/2 ASSAY 100 CLEARVIEW HIV 1/2 STAT-PAK 100 REVEAL G3 RAPID HIV-1 ANTIBODY TEST
8 PRISM HIV AG/AB COMBO ASSAY 100 SELECTED CD4 TESTS 100 BD FACSCALIBUR FLOW CYTOMETER 101 CYTOMICS FC 500 MCL/MPL SYSTEM 101 CYFLOW COUNTER 101 MILLIPORE-GUAVA AUTO CD4/CD4% SYSTEM 102 APOGEE AUTO40 FLOW CYTOMETER 102 AQUIOS CL 102 POINT OF CARE CD4 TESTING ASSAYS 102 PointCare NOW 102 Pima CD4 Analyser 102 CyFlowTM CD4 minipoc 103 SELECTED VIRAL LOAD TESTS 103 COBAS AMPLIPREP/COBAS TAQMAN HIV-1 SYSTEM 103 ABBOTT REALTIME HIV VERSANT HIV RNA 1.0 (KPCR) 104 ARTUS HIV-1 RS/QS-RGQ KIT 104 NUCLISENS EASYQ HIV VERSANT HIV-1 RNA 3.0 ASSAY 104 NON-NUCLEIC ACID-BASED VIRAL LOAD ASSAYS 104 ExaVir Load Version HIV DIAGNOSTICS PIPELINE 105 TABLE 47 HIV/AIDS DIAGNOSTICS PIPELINE 105 DAKTARI CD4 COUNTER 106 MBIO CD4 SYSTEM 106 VISITECT CD4 107 ZYOMYX MYT4 TEST 107 ALERE'S NAT SYSTEM 107 LIAT ANALYSER 108 SAMBA 108 EOSCAPE-HIV RAPID RNA ASSAY SYSTEM 109 LYNX HIV P24 ANTIGEN ASSAY 109 PANNAT PLATFORM 109 HIV DIAGNOSTICS MARKET 109 TABLE 48 HIV DIAGNOSTICS MARKET BY TYPES OF TESTS, THROUGH 2018 ($ TABLE 49 HIV DIAGNOSTICS MARKET SHARE BY TYPES OF TESTS, (%) 110 RAPID HIV TESTING MARKET 110 Forecast for Rapid HIV Testing Market 111 CD4 TESTING MARKET 111 TABLE 50 CD4 TESTING MARKET SHARE IN SEVEN SUB-SAHARAN AFRICAN COUNTRIES, 2012 (%) Forecast for CD4 Testing Market 112 TABLE 51 GLOBAL DEMAND FOR CD4 TESTING, (MILLIONS) 112 VIRAL LOAD TESTING MARKET 112 Forecast for Viral Load Testing Market 112 TABLE 52 GLOBAL DEMAND FOR VIRAL LOAD TESTING, (MILLIONS) 113 CHAPTER SUMMARY
9 TABLE 53 MARKET DRIVERS AND RESTRAINTS FOR HIV TESTING PRODUCTS 114 CHAPTER 9 HIV PROPHYLAXIS 116 HIV PROPHYLAXIS BASED ON EXPOSURE 116 EARLY PROPHYLAXIS 116 PRE-EXPOSURE PROPHYLAXIS 116 CLINICAL STUDIES IN SUPPORT OF HIV PREP 117 Bangkok Tenofovir Study 117 HPTN PopART Study 117 LONG ACTING FORMULATIONS OF EXISTING ARV DRUGS 118 TABLE 54 CLINICAL TRIALS TESTING DRUG-BASED PREP, 2014 AND MICROBICIDES AND VAGINAL RINGS 119 Centers for Disease Control and Prevention 119 Failure of the VOICE Trial 120 CAPRISA 120 ASPIRE and "IPM 027" 120 TABLE 55 ONGOING CLINICAL TRIALS OF MICROBICIDES, 2014 AND MALE CIRCUMCISION 122 POST-EXPOSURE PROPHYLAXIS (PEP) 122 PREVENTING TRANSMISSION FROM MOTHER TO CHILD 123 TABLE 56 EVOLUTION OF WHO GUIDELINES WITH REGARDS TO PMTCT, TABLE 57 SELECTED ON-GOING TRIALS ON PMTCT, CHAPTER SUMMARY 127 CHAPTER 10 HIV VACCINES 129 HURDLES FOR DEVELOPING HIV VACCINES 129 PROPHYLACTIC VS. THERAPEUTIC HIV VACCINES 129 TYPES OF HIV VACCINES 130 TABLE 58 TYPE OF HIV VACCINES 130 THE HISTORIC RV144 TRIAL 131 RECENT ADVANCES IN HIV VACCINE RESEARCH 132 GEOVAX'S PROPHYLACTIC AND THERAPEUTIC VACCINE DUAL TECHNOLOGY TABLE 59 ONGOING CLINICAL TRIALS OF PROPHYLACTIC HIV VACCINES 132 TABLE 60 ONGOING CLINICAL TRIALS FOR THERAPEUTIC HIV VACCINES 133 FUTURE HOPES OF A SUCCESSFUL HIV VACCINE CHAPTER 11 QUALITATIVE ANALYSIS 137 PORTER'S 5 ANALYSIS 137 FIGURE 10 GLOBAL HIV THERAPEAUTICS MARKET ANALYSIS 137 COMPETITIVE RIVALRY WITHIN INDUSTRY 137 THREAT OF NEW ENTRANTS 138 THREAT OF SUBSTITUTE PRODUCTS 138 Leading Drugs on Patent Cliff 138 Drug Counterfeiting 138 BARGAINING POWER OF SUPPLIERS 139 BARGAINING POWER OF CUSTOMERS 139
10 TRIPS Flexibilities 139 Compulsory Licensing and Parallel Imports 139 Negotiations for Low-Priced Drugs 139 Promoting Free Trade 139 Patents for Public Health 140 CHALLENGES OF THE HIV MARKET 140 ACCESSIBILITY TO ARV THERAPY 140 ADHERENCE TO DRUG REGIMENS 140 TABLE 61 RETENTION TO TREATMENT (%) 141 P4P4P 141 Combination Pills 141 HIGH COST OF TREATMENT 142 First-Line vs. Second-Line Treatment 142 TABLE 62 FIRST-LINE VS. SECOND-LINE TREATMENT MEDIAN PRICE, 2012 (IN $US PER PERSON PER YEAR) Cost of STR FDC Pills 142 PEDIATRIC FORMULATIONS OF ARV DRUGS 143 LATE DIAGNOSIS OF HIV INFECTION 143 ACCESSIBILITY TO HIV DIAGNOSTICS 144 COMPLEXITY OF VIRAL LOAD TESTING 144 ADHERENCE CHALLENGES IN PRE-EXPOSURE PROPHYLAXIS 145 REGULATORY AND POLITICAL CHALLENGES 145 HIGH VARIABILITY OF HIV 145 OPPORTUNITIES FOR REVENUE GENERATION 146 DRUGS FOR TREATMENT-EXPERIENCED PATIENTS 146 DRUGS WITH LONG HALF-LIFE 146 EARLY INFANT DIAGNOSIS 146 PREVENTING TREATMENT SWITCHES 147 DECENTRALIZATION OF HIV TESTING 147 DEMAND FOR SIMPLE, IMPROVED LOW-COST TESTING DEVICES 147 DRIVERS OF THE HIV MARKET 148 LONGEVITY OF HIV-INFECTED PATIENTS 148 INCREASE IN AWARENESS PROGRAMS 148 INCREASE IN ACCESS TO THERAPEUTICS AND DIAGNOSTICS 148 FOURTH-GENERATION RAPID HIV TESTING 148 POINT-OF-CARE DIAGNOSTICS 149 IMPLICATIONS OF RECENT REGULATORY GUIDELINES 149 RESTRAINTS TO THE GROWTH OF HIV MARKET 150 SOCIAL STIGMA ASSOCIATED WITH HIV TESTING 150 HIGH PRICE FOR NEW DRUGS EVENTUALLY REDUCING THEIR UPTAKE 150 PMTCT WILL REDUCE PEDIATRIC HIV MARKET 150 ECONOMIC SLOWDOWN 150 HARMONIZATION 151 PUBLIC-PRIVATE PARTNERSHIPS 151 CORPORATE RESPONSIBILITY 152 HARMONY AMONG REGULATORY AGENCIES 152 CHAPTER SUMMARY 153 TABLE 63 CHALLENGES AND OPPORTUNITIES IN THE GLOBAL HIV MARKET
11 TABLE 64 MAJOR DRIVERS AND RESTRAINTS IN THE GLOBAL HIV MARKET 155 CHAPTER 12 COMPANY PROFILES 157 HIV THERAPEUTICS-LEADING COMPANIES 157 TABLE 65 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES, ($ FIGURE 11 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES (%) 157 ABBVIE INC 158 BRISTOL-MYERS SQUIBB 159 Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge) 159 GILEAD SCIENCES 159 JANSSEN THERAPEUTICS 160 MERCK & CO. INC 161 VIIV HEALTHCARE 162 U.S. headquarters 162 HIV DIAGNOSTICS: LEADING COMPANIES 163 ABBOTT LABORATORIES 163 ALERE 163 BD BIOSCIENCES 164 BD 164 ROCHE 165 SIEMENS HEALTHCARE DIAGNOSTICS 165 SELECTED EMERGING AND GENERIC COMPANIES IN THE GLOBAL HIV MARKET 166 ASPEN GROUP 166 KORONIS PHARMACEUTICALS (VDA PHARMA) 167 MYLAN 167 SANGAMO BIOSCIENCES CHAPTER 13 APPENDIX A: GLOSSARY 170 TABLE 66 GLOSSARY 170 CHAPTER 14 APPENDIX B: DRUG ACRONYMS 176 CHAPTER 15 APPENDIX C: ABBREVIATIONS 178 TABLE 67 ABBREVIATIONS 178
12 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL HIV MARKET, THROUGH 2018 ($ 11 TABLE 1 TOP 10 LEADING CAUSES OF DEATHS IN THE WORLD, 2011 (MILLIONS) 13 TABLE 2 BURDEN OF HIV BY GEOGRAPHICAL REGIONS 14 TABLE 3 MILESTONES IN THE HISTORY OF HIV 15 TABLE 4 LIFE CYCLE OF HIV-THERAPEUTICS TARGET POINTS 17 TABLE 5 FORECASTED NUMBER OF PEOPLE RECEIVING ARV THERAPY, (MILLIONS) TABLE 6 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, THROUGH 2018 ($ TABLE 7 ARV DRUGS MARKET SHARE BY GEOGRAPHIC REGIONS, (%) 23 TABLE 8 EUROPEAN COUNTRIES BY RATES OF HIV DIAGNOSIS (%) 26 TABLE 9 PATTERN OF HIV INFECTION BY EUROPEAN REGIONS, TABLE 10 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES, THROUGH 2018 ($ TABLE 11 HIV THERAPEUTICS MARKET SHARE BY EU5 COUNTRIES, (%) 27 TABLE 12 HIV PREVALENCE IN EU5 COUNTRIES, TABLE 13 RATE OF LATE DIAGNOSIS BY REGIONS OF THE U.K. (%) 29 TABLE 14 HIV PREVALENCE AND INCIDENCE OF NEW INFECTIONS IN ASIAN COUNTRIES, 2012 TABLE 15 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, THROUGH 2018 ($ TABLE 16 HIV MARKET SHARE BY LEADING ASIAN COUNTRIES, (%) 30 TABLE 17 FORECAST GLOBAL ANNUAL INVESTMENT IN HIV RESEARCH, THROUGH 2018 ($ TABLE 18 GLOBAL INVESTMENT SHARE BY AREA OF RESEARCH, (%) 33 TABLE 19 INVESTMENT BY DONOR TYPE (%) 34 TABLE 20 INVESTMENT IN HIV THERAPEUTICS BY DRUG SUBCATEGORIES IN 2012 (%) 35 TABLE 21 INVESTMENT BY MODE OF HIV PROPHYLAXIS (%) 36 TABLE 22 LEADING ARV DRUGS ON PATENT CLIFF 38 TABLE 23 DRIVERS AND RESTRAINTS OF GENERIC HIV MARKET 39 TABLE 24 DRIVERS AND RESTRAINTS OF GLOBAL HIV MARKET 40 TABLE 25 RECOMMENDED ARV TREATMENT BY THE WHO 43 TABLE 26 HIV THERAPEUTICS MARKET BY DRUG CATEGORY, THROUGH 2018 ($ TABLE 27 HIV THERAPEUTICS MARKET SHARE BY DRUG CATEGORY, (%) 45 TABLE 28 LIST OF APPROVED NRTIS (AND TABLE UNITS) 46 TABLE 29 LIST OF APPROVED NNRTIS 48 TABLE 30 LIST OF APPROVED PROTEASE INHIBITORS 50 TABLE 31 LIST OF APPROVED INTEGRASE INHIBITOR DRUGS 51 TABLE 32 LIST OF APPROVED ENTRY INHIBITORS 52 TABLE 33 LIST OF APPROVED STR FDC DRUGS 54 TABLE 34 MARKET DRIVERS AND RESTRAINTS OF ARV DRUGS, BY CLASS 56 TABLE 35 SALES REVENUE FORECAST OF LEADING HIV DRUGS, THROUGH 2018 ($ TABLE 36 HIV MARKET SHARE BY LEADING DRUGS (%) 59 TABLE 37 MARKET DRIVERS AND RESTRAINTS OF THE LEADING ARV DRUGS 74 TABLE 38 ONGOING CLINICAL TRIALS OF NNRTI DRUGS IN DEVELOPMENT 78 TABLE 39 ONGOING CLINICAL TRIALS OF STR FDC DRUGS
13 TABLE HEADING TABLE 40 ONGOING CLINICAL TRIALS OF EMERGING THERAPIES 85 TABLE 41 OVERVIEW OF ARV DRUGS IN DEVELOPMENT 89 TABLE 42 HIV RAPID TESTS ADVANTAGES AND DISADVANTAGES BY CLIA* COMPLEXITY AND GENERATION TABLE 43 FDA APPROVED ANTIBODY HIV TESTS 95 TABLE 44 FDA APPROVED ANTIGEN-ANTIBODY COMBO TESTS 96 TABLE 45 CD4 TESTS IN THE MARKET 97 TABLE 46 LIST OF MARKETED VIRAL LOAD TESTS 98 TABLE 47 HIV/AIDS DIAGNOSTICS PIPELINE 104 TABLE 48 HIV DIAGNOSTICS MARKET BY TYPES OF TESTS, THROUGH 2018 ($ TABLE 49 HIV DIAGNOSTICS MARKET SHARE BY TYPES OF TESTS, (%) 109 TABLE 50 CD4 TESTING MARKET SHARE IN SEVEN SUB-SAHARAN AFRICAN COUNTRIES, 2012 (%) TABLE 51 GLOBAL DEMAND FOR CD4 TESTING, (MILLIONS) 111 TABLE 52 GLOBAL DEMAND FOR VIRAL LOAD TESTING, (MILLIONS) 112 TABLE 53 MARKET DRIVERS AND RESTRAINTS FOR HIV TESTING PRODUCTS 113 TABLE 54 CLINICAL TRIALS TESTING DRUG-BASED PREP, 2014 AND TABLE 55 ONGOING CLINICAL TRIALS OF MICROBICIDES, 2014 AND TABLE 56 EVOLUTION OF WHO GUIDELINES WITH REGARDS TO PMTCT, TABLE 57 SELECTED ON-GOING TRIALS ON PMTCT, TABLE 58 TYPE OF HIV VACCINES 129 TABLE 59 ONGOING CLINICAL TRIALS OF PROPHYLACTIC HIV VACCINES 131 TABLE 60 ONGOING CLINICAL TRIALS FOR THERAPEUTIC HIV VACCINES 132 TABLE 61 RETENTION TO TREATMENT (%) 140 TABLE 62 FIRST-LINE VS. SECOND-LINE TREATMENT MEDIAN PRICE, 2012 (IN $US PER PERSON PER YEAR) TABLE 63 CHALLENGES AND OPPORTUNITIES IN THE GLOBAL HIV MARKET 153 TABLE 64 MAJOR DRIVERS AND RESTRAINTS IN THE GLOBAL HIV MARKET 154 TABLE 65 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES, ($ TABLE 66 GLOSSARY 169 TABLE 67 ABBREVIATIONS
14 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL HIV MARKET, ($ 11 FIGURE 1 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, ($ FIGURE 2 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES ($ 27 FIGURE 3 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, ($ FIGURE 4 GENERIC VS. BRANDED ARV DRUGS GLOBAL SALES REVENUE, ($ FIGURE 5 GENERIC ARV DRUGS GLOBAL SALES REVENUE GROWTH ($ MILLIONS/%) 37 FIGURE 6 HIV THERAPEUTICS MARKET BY DRUG CATEGORY (%) 45 FIGURE 7 HIV MARKET SHARE BY LEADING DRUGS (%) 59 FIGURE 8 RANKING (BY MARKET SHARE) OF LEADING ARV DRUGS, FIGURE 9 NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE 76 FIGURE 10 GLOBAL HIV THERAPEAUTICS MARKET ANALYSIS 136 FIGURE 11 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES (%)
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationKaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013
Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationTHE AVAILABILITY AND USE OF HIV DIAGNOSTICS: A 2012/2013 WHO SURVEY IN LOW-AND MIDDLE-INCOME COUNTRIES TECHNICAL REPORT
TECHNICAL REPORT AIDS MEDICINES AND DIAGNOSTICS SERVICE THE AVAILABILITY AND USE OF HIV DIAGNOSTICS: A 2012/2013 WHO SURVEY IN LOW-AND MIDDLE-INCOME COUNTRIES DECEMBER 2014 THE AVAILABILITY AND USE OF
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS
ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS FOD067A June 2014 Natraj Pandal Project Analyst ISBN: 1-56965-851-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationAdvancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new
Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new H I V / A I D S D e p a r t m e n t WHO HQ Meg Doherty, MD, MPH, PhD Coordinator Treatment and Care November 5, 2012 1 Overview
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTreatment and Care: Product portfolio
Treatment and Care: Product portfolio Dr Paula Munderi MRC/UVRI Uganda Research Unit on AIDS EDCTP Stakeholder Meeting on HIV/AIDS 3-4 September 2013 Summary Brief overview HIV Treatment Pipeline Key Questions
More informationHIV immunological and virological monitoring tools. Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011
HIV immunological and virological monitoring tools Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011 Monitoring HIV disease progression and treatment When to start ART? CD4 count When
More informationINTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationMedical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum
Medical Challenges of HIV/AIDS pandemic: The WHO perspective SOLTHIS HIV Forum Marco Vitoria HIV/AIDS Department World Health Organization September 2013 Topic 2002 2003 2006 2010 2013 When to start 1
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationQUESTIONS AND ANSWERS
CONTACTS: Clare Collins Lisa Rossi +1-412-641-7299 +1-412-641-8940 +1-412-770-8643 (mobile) +1-412-916-3315 (mobile) collcx@upmc.edu rossil@upmc.edu QUESTIONS AND ANSWERS MTN-016: HIV Prevention Agent
More informationRENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS BIO138A January 2015 Cheng-Yuk Lee Project Analyst ISBN: 1-62296-003-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 024 USA 866-285-7215 (toll-free
More informationTABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 CONTRIBUTIONS TO THE STUDY AND INTENDED AUDIENCE 1 SCOPE AND FORMAT 1 METHODOLOGY AND INFORMATION
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationMEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationReportback from the 2013 ICAAC in Denver, CO
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p3 p8 PrEP NEWS New tenofovir vaginal ring protects monkeys, PrEP uptake higher among women and young people. HIV CARE
More informationU.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE
U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationNUTRACEUTICALS: GLOBAL MARKETS
NUTRACEUTICALS: GLOBAL MARKETS FOD013E November 2014 Natraj Pandal Project Analyst ISBN: 1-56965-992-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationJAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationPegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
More informationSofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine
More informationDNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationConsolidated Donor Funded Procurement of HIV Diagnostics
Consolidated Donor Funded Procurement of HIV Diagnostics Meeting on HIV Diagnostic Global Demand Forecast Geneva, 9 April 2015 Mercedes Perez Gonzalez Prequalification Team Diagnostics Assessment Department
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationRADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS
RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationContraceptives: Technologies and Global Markets
A BCC Research Healthcare Report HLC085A Use this report to: Learn how shifting demographic and sociological factors such as population growth, proportion of young population, and perceptions about family
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationBlood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595
Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample
More informationMEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL ULTRASOUND DEVICES: TECHNOLOGIES AND GLOBAL MARKETS IAS040B October 2016 Paul Taylor Project Analyst ISBN: 1-62296-372-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationInternational Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard
International Partnership for Microbicides Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard Dr. Zeda Rosenberg February 20, 2007 The Face of HIV Globally Increasingly
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationGlobal Hepatitis B and C Diagnostics Market
Global Hepatitis B and C Diagnostics Market 2016-2020 Global Hepatitis B and C Diagnostics Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers
More informationTHERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationSleep apnea devices Market Research Report- Global Forecast To 2022
Report Information More information from: https://www.marketresearchfuture.com/reports/2061 Sleep apnea devices Market Research Report- Global Forecast To 2022 Report / Search Code: MRFR/HC/1529-HCRR Publish
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationDatamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis
Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]
More informationGlobal E-Cigarette & Vaporizer Market Research Report - Forecast 2011 to 2021
Report Information More information from: https://www.marketresearchfuture.com/reports/949 Global E-Cigarette & Vaporizer Market Research Report - Forecast 2011 to 2021 Report / Search Code: MRFR/F-B &
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationTHE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy
THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy LEARNING FROM THE HIV RESPONSE EVOLUTION OF AIDS DRUG PRICES: 2000-2008 Source: MSF (2008)
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,
More informationCANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More information# $ pages In Stock. Report Description
Attapulgite (Colloidal and Sorptive) Market for Cat Litter Absorbent, Oil & Gas, Agriculture, Paints & Coatings, Medical & Pharmaceutical and Other Enduse Industries - Global Industry Analysis, Size, Share,
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationBIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS
BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS HLC171B March 2016 Yojana Jeevane Project Analyst ISBN: 1-62296-257-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationAntifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
More informationINTERNATIONAL PARTNERSHIP FOR MICROBICIDES
INTERNATIONAL PARTNERSHIP FOR MICROBICIDES HIV/AIDS and the Millennium Development Goals: MICROBICIDES and THE NEED FOR LONG-TERM PREVENTION IPM mission: To prevent HIV transmission by supporting the development
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More information